<DOC>
	<DOCNO>NCT00089713</DOCNO>
	<brief_summary>This study comprise 3- 6-week hydrochlorothiazide run phase , follow 12 week double-blind treatment phase , follow 2 week single-blind follow-up hydrochlorothiazide treatment phase . The combined total duration patient participation approximately 17-20 week . Four double-blind treatment group approximately equal size ( 98 ) comprise study population : placebo various alagebrium dose group ( 10 , 50 , 150 mg/day ) .</brief_summary>
	<brief_title>Systolic Pressure Efficacy Safety Trial Alagebrium ( SPECTRA )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Men woman least 45 year age uncontrolled systolic hypertension measure office cuff ambulatory blood pressure monitoring device Willingness take current antihypertensive treatment place hydrochlorothiazide combination study medication . Any significant history , systemic illness , medical condition ( ) could lead difficulty comply protocol could confound interpretation data .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>antihypertensive agents/therapeutic use</keyword>
	<keyword>hypertension/drug therapy</keyword>
	<keyword>blood pressure</keyword>
</DOC>